In another study, orthotopic HCC murine models given anti-PD-1 antibodies with concurrent 30 Gy SBRT in three fractions were found to have higher levels of CD8+ T cell infiltration at the tumor site, significantly delayed tumor growth, and improved survival [102]. The gene discussed is CD8A; the disease is hepatocellular carcinoma.